$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000110465913037892 Filed on May 07, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.980M	$2.530M
YoY Change	57.31%	-22.39%
% of Gross Profit
Research & Development	$10.33M	$4.739M
YoY Change	118.06%	-17.73%
% of Gross Profit
Depreciation & Amortization	$148.0K	$136.0K
YoY Change	8.82%	70.0%
% of Gross Profit
Operating Expenses	$14.31M	$7.264M
YoY Change	96.99%	-19.47%
Operating Profit	-$14.31M	-$7.264M
YoY Change	96.99%
Interest Expense	$643.0K	$2.000K
YoY Change	32050.0%	-99.62%
% of Operating Profit
Other Income/Expense, Net	$2.000K	$10.00K
YoY Change	-80.0%
Pretax Income	-$14.90M	-$6.843M
YoY Change	117.73%	-0.68%
Income Tax	-$1.221M	$2.000K
% Of Pretax Income
Net Earnings	-$13.68M	-$6.845M
YoY Change	99.82%	-0.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$433.6K	-$275.5K
COMMON SHARES
Basic Shares Outstanding	31.55M shares	24.86M shares
Diluted Shares Outstanding	31.55M shares	24.86M shares

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.60M	$70.80M
YoY Change	15.25%	-31.06%
Cash & Equivalents	$79.43M	$22.04M
Short-Term Investments		$48.70M
Other Short-Term Assets	$1.400M	$200.0K
YoY Change	600.0%	0.0%
Inventory
Prepaid Expenses
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets	$83.03M	$71.00M
YoY Change	16.94%	-31.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.681M	$1.900M
YoY Change	-11.53%	90.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$2.100M
YoY Change		-4.55%
Other Assets	$100.0K	$100.0K
YoY Change	0.0%
Total Long-Term Assets	$59.99M	$62.30M
YoY Change	-3.71%	-28.72%
TOTAL ASSETS
Total Short-Term Assets	$83.03M	$71.00M
Total Long-Term Assets	$59.99M	$62.30M
Total Assets	$143.0M	$133.3M
YoY Change	7.29%	-30.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.184M	$2.900M
YoY Change	182.21%	-6.45%
Accrued Expenses	$5.329M	$1.000M
YoY Change	432.9%	11.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.875M	$100.0K
YoY Change	4775.0%	0.0%
Total Short-Term Liabilities	$20.27M	$4.100M
YoY Change	394.44%	-10.87%
LONG-TERM LIABILITIES
Long-Term Debt	$14.51M	$100.0K
YoY Change	14411.0%	0.0%
Other Long-Term Liabilities	$600.0K	$900.0K
YoY Change	-33.33%
Total Long-Term Liabilities	$14.51M	$1.000M
YoY Change	1351.1%	900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.27M	$4.100M
Total Long-Term Liabilities	$14.51M	$1.000M
Total Liabilities	$35.41M	$5.100M
YoY Change	594.33%	8.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$349.2M
YoY Change
Common Stock	$316.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$107.6M	$128.1M
YoY Change
Total Liabilities & Shareholders Equity	$143.0M	$133.3M
YoY Change	7.29%	-30.03%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$13.68M	-$6.845M
YoY Change	99.82%	-0.65%
Depreciation, Depletion And Amortization	$148.0K	$136.0K
YoY Change	8.82%	70.0%
Cash From Operating Activities	-$11.21M	-$5.610M
YoY Change	99.82%	9.78%
INVESTING ACTIVITIES
Capital Expenditures	$163.0K	$66.00K
YoY Change	146.97%	-760.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$12.91M
YoY Change	-100.0%	-21.76%
Cash From Investing Activities	-$160.0K	$12.84M
YoY Change	-101.25%	-22.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	-30.00K
YoY Change	-166.67%	50.0%
NET CHANGE
Cash From Operating Activities	-11.21M	-5.610M
Cash From Investing Activities	-160.0K	12.84M
Cash From Financing Activities	20.00K	-30.00K
Net Change In Cash	-11.35M	7.200M
YoY Change	-257.64%	-36.62%
FREE CASH FLOW
Cash From Operating Activities	-$11.21M	-$5.610M
Capital Expenditures	$163.0K	$66.00K
Free Cash Flow	-$11.37M	-$5.676M
YoY Change	100.37%	11.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31795357	shares
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	us-gaap	Assets Current AssetsCurrent	83025000	USD
CY2013Q1	us-gaap	Assets Assets	143016000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20272000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	35411000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2013Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2173000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13678000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	954000	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	797000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	107605000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143016000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90782000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1418000	USD
CY2013Q1	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2013Q1	us-gaap	Other Assets OtherAssets	110000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1681000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	316000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455725000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349226000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8184000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1359000	USD
CY2013Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	298000	USD
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	144000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	83000	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	4875000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10334000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	48000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3975000	USD
CY2013Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	51000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	643000	USD
CY2013Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31554000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1124000	USD
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31571926	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31571926	shares
CY2013Q1	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-64000	USD
CY2013Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-848000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	34000	USD
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Use of Estimates -</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances.  The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each period presented are effected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, stock-based compensation, income taxes, loss contingencies, the warrant fair value calculation, impairment of intangibles and long lived assets and accounting for research and development costs.  Actual results could differ from those estimates.</font> </div>
CY2013Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Concentration of Credit Risk</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company places its cash equivalents with financial institutions that it believes have high credit quality. The Company has established investment guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Company sources each of its raw materials from a single supplier.  In addition, the production of the Company’s lead product candidate is performed by a sole manufacturer. The inability of the suppliers or manufacturer to fulfill supply requirements of the Company could materially adversely affect future operating results or the Company’s business generally. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially adversely affect the Company’s future operating results.</font></p> </div>
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	29000	USD
CY2013Q1	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	2941000	USD
CY2012Q4	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	1460000	USD
CY2013Q1	insm	Liability For Stock Based Compensation Awards LiabilityForStockBasedCompensationAwards	1808000	USD
CY2012Q4	insm	Liability For Stock Based Compensation Awards LiabilityForStockBasedCompensationAwards	1204000	USD
CY2013Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	417000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	185000	USD
CY2013Q1	us-gaap	Interest Payable Current InterestPayableCurrent	159000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	80000	USD
CY2012Q2	insm	Number Of Secured Promissory Notes NumberOfSecuredPromissoryNotes	2	item
CY2013Q1	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2013Q1	insm	Additional Charge At End Of Term AdditionalChargeAtEndOfTerm	92000	USD
CY2013Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	169000	USD
CY2013Q1	insm	Unamortized Discount From Warrant UnamortizedDiscountFromWarrant	537000	USD
CY2013Q1	us-gaap	Debt Current DebtCurrent	-4875000	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14511000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3007000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7724000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	8481000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	788000	USD
CY2013Q1	us-gaap	Long Term Debt LongTermDebt	20000000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3014000	USD
CY2013Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2012Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	890000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1201000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	498000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	425000	USD
CY2013Q1	insm	Proceeds From Sale Of Nol Net ProceedsFromSaleOfNOLNet	1200000	USD
CY2013Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.082	pure
CY2012Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	350000000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1221000	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2013Q1	insm	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	item
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1817839	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	552250	shares
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	17170	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	5000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2347919	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2180927	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	426919	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.74
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.85
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.03
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6092692	USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1304426	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.10
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.72
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.57
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M8D
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y29D
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y3M7D
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6507867	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2011	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio StockholdersEquityNoteStockSplitConversionRatio	0.1	pure
CY2013Q1	us-gaap	Interest Paid InterestPaid	476000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4739000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	14309000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14309000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14899000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13678000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2525000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	2000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11348000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	118000	USD
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2153000	USD
CY2012Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	418000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	2000	USD
CY2013Q1	insm	Number Of Initial Indications In Orphan Patient Populations For Which Clinical Trials Conducted NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted	2	item
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6845000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31554000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24860000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31554000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24860000	shares
CY2013Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2012Q4	us-gaap	Assets Current AssetsCurrent	93578000	USD
CY2012Q4	us-gaap	Assets Assets	153561000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15747000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	32679000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	120882000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153561000	USD
CY2012Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	5000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	7264000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7264000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6843000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7195000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31488204	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31488204	shares
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5329000	USD
CY2013Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	580000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	643000	USD
CY2013Q1	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	1787000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14848000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11209000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5612000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-161000	USD
CY2012Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	647000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	12841000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	64000	USD
CY2013Q1	us-gaap	Accretion Expense AccretionExpense	49000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-263000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	545000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-34000	USD
CY2012Q1	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	-609000	USD
CY2012Q1	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-64000	USD
CY2012Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-285000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-757000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79434000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22043000	USD
CY2012Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	216000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4000	USD
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24860000	shares
CY2012Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	216000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6629000	USD
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2012Q4	us-gaap	Other Assets OtherAssets	117000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1666000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7060000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2933000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2207000	USD
CY2012Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	295000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	149000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	96000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3007000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16221000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	315000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455325000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	790000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	790000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335548000	USD
CY2013Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	329932	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	329932	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.94
CY2012Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.94
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	136000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	495000	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	12907000	USD
CY2012Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD

Files In Submission

Name	View Source	Status
0001104659-13-037892-index-headers.html	Edgar Link	pending
0001104659-13-037892-index.html	Edgar Link	pending
0001104659-13-037892.txt	Edgar Link	pending
0001104659-13-037892-xbrl.zip	Edgar Link	pending
a13-10493_110q.htm	Edgar Link	pending
a13-10493_1ex10d1.htm	Edgar Link	pending
a13-10493_1ex10d2.htm	Edgar Link	pending
a13-10493_1ex10d3.htm	Edgar Link	pending
a13-10493_1ex31d1.htm	Edgar Link	pending
a13-10493_1ex31d2.htm	Edgar Link	pending
a13-10493_1ex32d1.htm	Edgar Link	pending
a13-10493_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
insm-20130331.xml	Edgar Link	completed
insm-20130331.xsd	Edgar Link	pending
insm-20130331_cal.xml	Edgar Link	unprocessable
insm-20130331_def.xml	Edgar Link	unprocessable
insm-20130331_lab.xml	Edgar Link	unprocessable
insm-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2013 Q1 Form 10-Q Financial Statement

#000110465913037892 Filed on May 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2013 Q1 Form 10-Q Financial Statement

#000110465913037892 Filed on May 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm